6JULY - 2023TECH OUTLOOKEditorialStacey Smith Editor-in-Chiefeditor@pharmatechoutlook.comIn the realm of healthcare, a powerful revolution is underway, driven by the growing recognition of medical cannabis as a transformative therapeutic option. Long shrouded in controversy, cannabis is shedding its negative stigma and emerging as a beacon of hope for countless individuals seeking relief from debilitating conditions. Deep within the intricate chemistry of the cannabis plant lies a treasure trove of healing compounds, known as cannabinoids. These compounds interact with our body's endocannabinoid system, playing a crucial role in maintaining balance and homeostasis. From pain relief and anti-inflammatory effects to anxiety reduction and anti-seizure potential, medical cannabis holds promise across a wide range of conditions. By tapping into nature's pharmacy, we unlock a world of possibilities for patients seeking alternative treatments.The legal landscape surrounding medical cannabis is a patchwork of varying regulations and perspectives across different jurisdictions. While some countries and states have embraced the therapeutic potential of cannabis and implemented comprehensive frameworks, others are still grappling with outdated laws. As society's understanding of medical cannabis evolves, it becomes increasingly crucial to advocate for sensible regulations that prioritize patient access, product safety, and responsible use.According to Grand View Research, the global medical marijuana market size was valued at USD 13.8 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 21.80 percent from 2023 to 2030. The industry is experiencing growth due to the rising awareness regarding various therapeutic applications of the product, such as pain management, appetite enhancement, and reducing eye pressure.This edition of Pharma Tech Outlook Europe delves into the key developments in the medical cannabis space and how companies are aligning with these trends to offer robust healthcare solutions to their customers. We have curated thought leadership articles from industry experts, including Erika Vento-Gaudens, Director, Global Clinical Trial Operations at Guardant Health and Tony Street, Vice President for Clinical Trial Supplies, Orifarm.We also took a deep dive into the market trends to narrow down the list of top medical cannabis providers. Equipped with innovative technological capabilities, companies such as IMCI Pharmaceuticals help transform businesses at the cloverleaf of various disruptive technologies.We hope this edition of the Pharma Tech Outlook Europe on Medical Cannabis helps you build the partnership you and your organization need to foster an environment driven by efficient technology.Medical Cannabis: Unveiling Nature's Therapeutic ArsenalCopyright © 2023 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.JULY - 10 - 2023, Vol 09 - Issue 08 (ISSN 2644-2787) Published by ValleyMedia, Inc. To subscribe to Pharma Tech OutlookVisit www.pharmatechoutlook.com Disclaimer: *Some of the Insights are based on our interviews with CIOs and CXOsEditor-in-ChiefStacey SmithVisualizerRonald DonovanEditorial StaffAaron Pierce Ava GarciaJenna VegasCarolynn Walters Justin SmithPaul Barbersales@pharmatechoutlook.comeditor@pharmatechoutlook.commarketing@pharmatechoutlook.comEmail:Parley MeadowTECH OUTLOOKTECH OUTLOOK
< Page 5 | Page 7 >